Astria Therapeutics Inc (ATXS) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ATXS Annual Balance Sheets →
From Astria Therapeutics Inc through Sep 30 2024, shifts in Sep 30 2025's assets and liabilities provide insight into the company's capital structure and financial stability.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2025)
(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Assets
Cash & cash equivalent96.28
Short-term Investments, Total131.44
Cash & Short-term Investments227.00
Accounts receivable17.24
Prepaid Expense And Other Assets Current8.58
Total Current Assets253.55
Other Assets, Noncurrent18.00
Operating Lease Right Of Use Asset4.25
Total Assets271.87
Liabilities
Accounts Payable, Current AC1.14
Accrued Liabilities, Current AC16.48
Other Liabilities, Current1.40
Deferred Revenue, Current DE4.50
Total Current Liabilities23.52
Total Long-term Debt0.00
Deferred Revenue, Noncurrent DE12.04
Other liabilities, Noncurrent3.06
Operating Lease Liability Current1.40
Operating Lease Liability Noncurrent3.06
Total Liabilities38.61
Stockholders' Equity
Common Stock Value0.06
Additional Paid In Capital Common Stock911.01
Retained Earnings / Accumulated Deficit-773.20
Other Equity95.38
Common Stockholder's Equity233.25
Total Stockholder's Equity233.25
Liabilities & Stockholder's Equity271.87
4 historic quarters locked

Sign in to unlock the full Astria Therapeutics Inc balance sheet history.

About Astria Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-25-110377

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.